Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy

The goal of this clinical trial is to assess whether the addition of preoperative stereotactic body radiation therapy (SBRT) can improve pathological complete response (pCR) rates and safety in breast cancer patients who do not respond to initial neoadjuvant chemotherapy. The main questions it aims to answer are: * Can the combination of SBRT with chemotherapy increase pCR rates in non-responders to initial neoadjuvant chemotherapy? * Does the addition of SBRT to chemotherapy have acceptable safety and tolerability profiles? Participants in this trial will be early or locally advanced breast

Trial Details

NCT ID
NCT06596018
Phase
PHASE1 / PHASE2
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • SBRT
  • Chemotherapy
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Confirmed histologic diagnosis of invasive adenocarcinoma of the breast;
  • Stage T1-4N+M0 breast cancer (i.e., stages II and III);
  • Breast MRI showing no extracapsular extension of lymph node involvement;
  • The standard neoadjuvant chemotherapy regimen has been deemed ineffective after two cycles, with disease assessed as stable (SD) or progressive (PD…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →